Clinical Trial Detail

NCT ID NCT03428126
Title Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

colorectal cancer

Therapies

Durvalumab + Trametinib

Age Groups: senior adult

No variant requirements are available.